

Index

A

ACPAs. *See* Antibodies to citrullinated peptide antigens
Activation-induced cell death (AICD), 25
AICD. *See* Activation-induced cell death
AIRE, 3, 18–19, 24, 88, 103–104
AKT, 35
Alefacept, 136
ALPS. *See* Autoimmune lymphoproliferative syndrome
ALS. *See* Antilymphocyte serum
Altered peptide ligands (APLs), tolerance restoration in
 autoimmunity, 134–135
AMPK, 23
Anergy
 B cell, 56
 T-cell peripheral tolerance, 23–24
Anti-CD3. *See* OKT3
Antibodies to citrullinated peptide antigens (ACPAs), 91
Antigen-presenting cell (APC). *See also specific cells*
 history of study, 4
 T cell
 central tolerance
 dendritic cell, 19, 51
 medullary thymic epithelial cell, 18–19
 peripheral tolerance, 24–25
 therapeutic targeting in autoimmune disease, 137
 tolerogenic cells, 24–25
Antilymphocyte serum (ALS), tolerance restoration in
 autoimmunity, 130
Antithymocyte globulin (ATG), tolerance restoration in
 autoimmunity, 130
APC. *See* Antigen-presenting cell
APECED. *See* Autoimmune polyendocrinopathy can-
 didiasis ectodermal dystrophy
APLs. *See* Altered peptide ligands
APS-1. *See* Autoimmune polyendocrine syndrome type 1
ATG. *See* Antithymocyte globulin
Autoimmune lymphoproliferative syndrome (ALPS), 87
Autoimmune polyendocrine syndrome type 1 (APS-1),
 87, 93
Autoimmune polyendocrinopathy candidiasis ectoder-
 mal dystrophy syndrome (APECED), 18,
 93, 127
Autoimmunity. *See also specific diseases*
 commensal microbiota effects
 microbial lineage effects, 106–108
 overview, 103–105
 promotion mechanisms, 105–106

 protective effects, 108–109
commensalism establishment
 legume–rhizobia symbiosis, 116–117
 mammalian conserved signals, 118–119
 nematode–*Xenorhabdus* symbiosis, 118
 squid–*Vibrio fischeri* symbiosis, 117–118
environmental influences, 103–105
genetics
 architecture, 89–91
 clinical application, 91
 hidden genetic risk, 94–96
 human leukocyte antigen haplotypes, 91–92
 polymorphisms
 common risk variants, 92–93
 disease-specific risk variants, 93–94
 prospects for study, 96–97
 strategies for gene identification, 88–89
history of study, 7–9
human gene mutations in microbial recognition,
 119–120
immunotolerance study prospects, 122–123
infectious inflammation as frustrated
 commensalism, 120–122
tolerance restoration through immunomodulation
 antigen-specific immunotherapy, 133–136
 cellular therapies, 138–141
 prospects, 141
 systemic immunotherapy, 130–133
 T-cell costimulation targeting, 136–138
 targets, 128–130

B

BAFF, 68–69
B cell
 anergy, 5–6
 autoimmune disease therapeutic targeting, 133
 central tolerance
 clonal deletion, 61
 cytokines, 68–69
 low-avidity interactions, 65
 overview, 59–61
 positive selection of immature B cells, 66–68
 prospects for study, 69–70
 receptor editing
 hazards, 65–66
 overview, 61–62
 tolerance role, 63–65

Index

- B-cell receptor (BCR)
 B-cell anergy role, 5
 editing
 hazards, 65–66
 overview, 61–62
 tolerance role, 63–65
 history of central tolerance studies, 2
 signaling in immature cells, 66–68
- Bcl-2, 67
- BCR. *See* B-cell receptor
- BIM, 20, 25
- Blimp-1, 53
- C**
- CARMA1, 35
- CD5, 3
- CD40, therapeutic targeting in autoimmune disease, 137
- CD154, therapeutic targeting in autoimmune disease, 137
- Central tolerance
 B cell
 clonal deletion, 61
 cytokines, 68–69
 low-avidity interactions, 65
 overview, 59–61
 positive selection of immature B cells, 66–68
 prospects for study, 69–70
 receptor editing
 hazards, 65–66
 overview, 61–62
 tolerance role, 63–65
 history of study, 2–3
 T cell
 antigen-presenting cells
 dendritic cell, 19
 medullary thymic epithelial cell, 18–19
 clonal deletion
 clonal diversion distinction, 22–23
 mechanisms, 19–21
 stages, 16–18
 clonal diversion, 21–23
 overview, 15–16
- Chronic inflammatory demyelinating polyneuropathy (CIDP), 133
- CIDP. *See* Chronic inflammatory demyelinating polyneuropathy
- Clonal deletion
 B-cell central tolerance, 61
 T cell
 clonal diversion distinction, 22–23
 mechanisms, 19–21
 stages, 16–18
- Clonal diversion, T cell, 21–23
- Cohn, Zanvil, 45
- Commensal microbiota
 autoimmunity effects
 microbial lineage effects, 106–108
 overview, 103–105
 promotion mechanisms, 105–106
 protective effects, 108–109
 health maintenance overview, 101–102
- Costimulation
 anergy, 23–24
 history of study, 4–6
 T-cell clonal deletion, 21
 targeting in autoimmune disease treatment, 136–138
- Crohn's disease, 53, 89, 91, 137–138
- CTLA-4, 89
 autoimmunity polymorphisms, 8
 costimulation, 5, 25
 dominant tolerance role, 4
 T-cell anergy role, 24
 tolerance restoration therapies in autoimmunity, 130, 136
- D**
- DAMPs. *See* Danger-associated molecular patterns
- Danger-associated molecular patterns (DAMPs), 5
- DC. *See* Dendritic cell
- DCLRE1C*, autoimmune disease polymorphisms, 92
- Dendritic cell (DC)
 history of study, 45–46
 lineage, 46–47
 pathogens in subversion, 50–51
 peripheral tolerance studies
 cell loss impact, 52
 intrinsic breach of immune tolerance, 52–52
 regulatory T-cell homeostasis, 53–54
 self-antigen presentation, 51–52
 prospects for study, 54
 subsets
 heterogeneity, 46–47
 humans, 48–49
 tolerance implications, 49–50
 targeting in autoimmune disease treatment, 140
- T-cell interactions
 central tolerance role, 19, 51
 peripheral tolerance role, 24–25
 response initiation, 50
- Diabetes type 1
 islet destruction mechanisms, 8–9
 susceptibility loci, 7–8, 90
 tolerance restoration in autoimmunity, 132, 134–136, 139–140
- Dominant tolerance, history of study, 3–4
- E**
- Efalizumab, 137
- ERK. *See* Extracellular signal-regulated kinase
- Extracellular signal-regulated kinase (ERK), 20

- F**
Fas
 mutation in autoimmunity, 88
 T-cell peripheral deletion role, 25
Fingolimod, 137
Flt3 L, 53
FoxP3, 21, 31, 88, 104
FoxP3+CD4+ T cell. *See* Regulatory T cell
FTY720, 138
- G**
GAD65, 135
Genome-wide association study (GWAS),
 autoimmunity genes, 89, 94
Graft versus host disease (GVHD), 140
Guillain–Barré syndrome, 133
GVHD. *See* Graft versus host disease
GWAS. *See* Genome-wide association study
- H**
HEL, 65
Hematopoietic stem cell transplantation (HSCT),
 autoimmune disease treatment, 138–139
HIV. *See* Human immunodeficiency virus
HSCT. *See* Hematopoietic stem cell transplantation
Human immunodeficiency virus (HIV), 113
Human leukocyte antigen. *See* Major histocompatibility
 complex
- I**
IL-2. *See* Interleukin-2
IL2RA, autoimmune disease polymorphisms, 93
IL-7. *See* Interleukin-7
IL7RA, autoimmune disease polymorphisms, 92
IL23R, autoimmune disease polymorphisms, 93
Immunodysregulation, polyendocrinopathy, and
 enteropathy X-linked syndrome (IPEX),
 87, 93, 104, 127
Inflammation
 infectious inflammation as frustrated
 commensalism, 120–122
 targeting in autoimmune disease treatment,
 136–138
Interleukin-2 (IL-2)
 autoimmunity role, 9
 dominant tolerance role, 4
 tolerance restoration in autoimmunity, 132
 Treg induction, 34
Interleukin-7 (IL-7), 68
Intravenous immunoglobulin (IVIG), tolerance restor-
 ation in autoimmunity, 133
IPEX. *See* Immunodysregulation, polyendocrinopathy,
 and enteropathy X-linked syndrome
- IRAK4, 119
Irf4, 37–38
IVIG. *See* Intravenous immunoglobulin
- K**
KAZALDI, autoimmune disease polymorphisms, 94
- L**
Langerhans, Paul, 45
LCMV. *See* Lymphocyte choriomeningitis virus
Listeria, dendritic cell subversion, 51
LNSC. *See* Lymph node stromal cell
Lymph node stromal cell (LNSC), T-cell peripheral
 tolerance role, 24–25
Lymphocyte choriomeningitis virus (LCMV), 105
- M**
Major histocompatibility complex (MHC)
 autoimmune disease human leukocyte antigen
 haplotypes, 91–92
 class II molecules in tolerance restoration in
 autoimmunity, 133–134
 diabetes type 1 susceptibility loci, 7
 natural killer cell tolerance and class I molecules
 MHC-I-independent tolerance mechanisms,
 79–82
 role, 76, 79
Mammalian target of rapamycin (mTOR), 23
MBP. *See* Myelin basic protein
Medullary thymic epithelial cell (mTEC), T-cell central
 tolerance role, 18–19, 129
Mesenchymal stem cell (MSC), autoimmune disease
 treatment, 139
MHC. *See* Major histocompatibility complex
Microbial-associated molecular patterns. *See* Pathogen-
 associated molecular patterns
Microbiota. *See* Commensal microbiota
MS. *See* Multiple sclerosis
MSC. *See* Mesenchymal stem cell
mTEC. *See* Medullary thymic epithelial cell
mTOR. *See* Mammalian target of rapamycin
Multiple sclerosis (MS)
 genetics, 88–89, 92
 therapeutic targets, 133–140
MyD88, 119
Myelin basic protein (MBP), 134–135
- N**
Natural killer (NK) cell
 functional overview, 75–76
 invariant cells, 102
 major histocompatibility complex class I molecules

Index

- Natural killer (NK) cell (*Continued.*)
MHC-I-independent tolerance mechanisms, 79–82
tolerance role, 76, 79
reactivity analysis models, 77–78
tolerance
breaking, 83
maintenance, 82–83
prospects for study, 83
NF- κ B. *See* Nuclear factor- κ B
Nitric oxide synthase (NOS), 117, 122
NK cell. *See* Natural killer cell
NKG2D, 75, 82
NOS. *See* Nitric oxide synthase
Nuclear factor- κ B (NF- κ B), 4, 35
NUR77, 20, 35
- O**
- OKT3, tolerance restoration in autoimmunity, 131
Owen, Ray, 2
- P**
- PAMPs. *See* Pathogen-associated molecular patterns
Pathogen-associated molecular patterns (PAMPs), 4, 103, 115–117, 120, 122
Pattern recognition receptors (PRRs), 114–116, 119–120
PD-1, 24
Peripheral tolerance, T cell
anergy, 23–24
antigen-presenting cells, 24–25
dendritic cell studies
cell loss impact, 52
intrinsic breach of immune tolerance, 52–52
regulatory T-cell homeostasis, 53–54
self-antigen presentation, 51–52
overview, 23
peripheral deletion, 25
Plasmacytoid dendritic cell (pDC), 46, 50
PRRs. *See* Pattern recognition receptors
PTPN22, autoimmune disease polymorphisms, 89, 91, 93–94
- R**
- RA. *See* Rheumatoid arthritis
RAG1, autoimmune disease polymorphisms, 92
Rapamycin, T-cell anergy induction, 23
Regulatory T cell (Treg)
dendritic cell in homeostasis, 53–54
differentiation, 32–35
diversity, 37–38
effector strategies, 37
functional overview, 31–32
history of study
dominant tolerance, 3–4
immunoregulation, 6–7
intravenous immunoglobulin effects, 133
iTreg, 6
location and migration, 36–37
phenotypic stability, 35–36
pTreg, 33–34
T-cell receptor repertoire, 36
therapeutic targeting in autoimmunity, 140–141
Tr1 cell, 6
tTreg, 33
Rheumatoid arthritis (RA), 94, 133, 136
Rhizobia. *See* Commensal microbiota
Rituximab, tolerance restoration in autoimmunity, 133
RMRB, autoimmune disease polymorphisms, 92
- S**
- SLE. *See* Systemic lupus erythematosus
Steinman, Ralph, 45
Symbiosis. *See* Commensal microbiota
Systemic lupus erythematosus (SLE), 6, 8, 92
- T**
- TAK1, 35
Tbet, 37
T cell. *See also specific T cells*
central tolerance
antigen-presenting cells
dendritic cell, 19, 51
medullary thymic epithelial cell, 18–19
clonal deletion
clonal diversion distinction, 22–23
mechanisms, 19–21
stages, 16–18
clonal diversion, 21–23
overview, 15–16
peripheral tolerance
anergy, 23–24
antigen-presenting cells, 24–25
dendritic cell studies
cell loss impact, 52
intrinsic breach of immune tolerance, 52–52
regulatory T-cell homeostasis, 53–54
self-antigen presentation, 51–52
overview, 23
peripheral deletion, 25
therapeutic targeting in autoimmune disease, 129–130
T-cell receptor (TCR)
activation, 5
clonal diversion, 21
costimulation, 21

- history of central tolerance studies, 2–3
 - transgenic mice, 140–141
 - Treg, 34–36
 - TCR. *See* T-cell receptor
 - T helper (Th) cell
 - effectors, 31
 - pathogen specificity, 6
 - Th17, 35, 37–38
 - TGF- β . *See* Transforming growth factor- β
 - Th cell. *See* T helper cell
 - TLRs. *See* Toll-like receptors
 - TNF- α . *See* Tumor necrosis factor- α
 - Tolerance. *See* Autoimmunity; Central tolerance; Dominant tolerance; Peripheral tolerance
 - Toll-like receptors (TLRs), 4, 8, 115, 119
 - Toxoplasma*, dendritic cell subversion, 50
 - TRAF3, 119
 - TRAF6, 19
 - Transforming growth factor- β (TGF- β)
 - clonal diversion role, 22
 - dominant tolerance role, 4
 - regulatory T cell
 - induction, 34
 - secretion, 36
 - therapeutic targeting in autoimmune disease, 130
 - Treg. *See* Regulatory T cell
 - Tuberculosis, 113, 121–122
 - Tumor necrosis factor- α (TNF- α), targeting in autoimmune disease treatment, 136, 138
- U**
- UNC93B, 119
- V**
- V(D)J recombination, 62–63, 67
 - Vibrio fischeri*. *See* Commensal microbiota
- X**
- Xenorhabdus*. *See* Commensal microbiota